<DOC>
	<DOCNO>NCT00450398</DOCNO>
	<brief_summary>The study design assess feasibility evaluate YSPSL amelioration ischemia reperfusion injury follow liver transplantation administer YSPSL liver graft directly ex vivo via portal vein recipient intravenously prior reperfusion . Recently , P-selectin expression associate liver graft prolong cold storage time rejection . By examine biomarkers IRI include P-selectin immunohistochemistry and/or quantitative PCR , liver histology hepatic blood flow use establish technique , goal study evaluate feasibility use modality future study safety efficacy .</brief_summary>
	<brief_title>YSPSL Prevention Delayed Graft Function Cadaveric Liver Transplantation</brief_title>
	<detailed_description>This single-center , single-dose study . The study randomize , double-blind , placebo-controlled , single-dose study . Patients undergo cadaveric orthotopic liver transplantation risk development DGF , base upon know risk factor , eligible participate study . 12 patient enrol study .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>1 . Patient recipient primary ( first ) ABO compatible cadaveric liver allograft ; 2 . Patient 's age &gt; =18 year ; 3 . Patient recipient multivisceral transplant simultaneous kidney transplant ; 4 . Patient undergone prior organ cellular transplant type ; 5 . Patient Model End Stage Liver Disease ( MELD ) score &lt; 28 ; 6 . Cold ischemia time ( CIT ) anticipate less 12 hour ; 7 . Donor liver procure UCLA liver team ; 8 . Venoveno bypass plan use patient ( e.g . prior surgery factor indicate risk excessive blood loss therefore need venoveno bypass +/ autologous recovery surgery ) ; 9 . For patient woman childbearing potential , patient negative pregnancy test ( either urine serum ) within 48 hour prior transplant ; 10 . Patient ( male female ) willing use acceptable form birth control least 3 month posttreatment ; 11 . Patient willing able sign inform consent . 1 . Patient prior organ transplant type ; 2 . Patient know allergic intolerance reaction human immune globulin , antibody , component formulation know contraindication administration YSPSL ; 3 . Patient uncontrolled active infection ( antibiotic control infection exclusion ) ; 4 . Patient active Hepatitis B virus ( HBV ) /transplant HBV related cirrhosis ; 5 . Patient previously participate study another study YSPSL ; 6 . Patient receive investigational therapy within 90 day prior transplant procedure ; 7 . Patient current drug alcohol abuse , opinion investigator , risk poor compliance visit protocol ( drug testing require ) ; 8 . Patient pregnant nursing female , female childbearing potential planning become pregnant within duration study , practice birth control ; 9 . Patient plan receive living donor liver transplant ; 10 . Patient live &gt; 200 mile away otherwise able participate study followup visit ; 11 . Donor body mass index &gt; 28 ; 12 . Donor liver biopsy &gt; 20 % macrosteototic fat ; 13 . Donor age &gt; 65 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Delayed graft function</keyword>
</DOC>